ERBB2 and breast cancer: Although BC incidence remains high, an increase in overall survival (OS) has been attributed to advances in early detection programmes and therapeutic approaches directed against molecular biomarkers, such as hormone receptors and HER2, which are overexpressed and amplified in luminal and HER2 subtypes, respectively.